Key result
NeoVas bioresorbable scaffolds showed promising efficacy and safety at 3 years of follow-up in a low-risk population with noncomplex coronary artery disease.
Why the study?
Do NeoVas bioresorbable scaffolds show efficacy and safety in low-risk patients with noncomplex coronary artery disease?
Do NeoVas bioresorbable scaffolds show efficacy and safety in low-risk patients with noncomplex coronary artery disease?
NeoVas bioresorbable scaffolds may be a viable option for low-risk patients with noncomplex coronary artery disease when proper patient and lesion selection are applied.
Key Points NeoVas bioresorbable scaffolds (BRS) showed promising results in terms of efficacy and safety at 3 years of follow‐up in a low‐risk population with noncomplex coronary artery disease. Proper patient, lesion selection, and implantation technique are the keys to achieve optimal procedural and clinical results. New platforms with improved radial strength and shorter resorption time could promote BRS spread to a higher risk population.
No takes yet. Share an insight, caveat, or question.
Musumeci et al. (2023) conducted an editorial in Low-risk coronary artery disease. NeoVas bioresorbable scaffolds (BRS) was evaluated. NeoVas bioresorbable scaffolds showed promising efficacy and safety at 3 years of follow-up in a low-risk population with noncomplex coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: